JNJ

190.85

-0.66%↓

ABT

126.63

+0.17%↑

MDT

93.85

-0.53%↓

VEEV

293.38

+0.69%↑

A

148.14

+0.67%↑

JNJ

190.85

-0.66%↓

ABT

126.63

+0.17%↑

MDT

93.85

-0.53%↓

VEEV

293.38

+0.69%↑

A

148.14

+0.67%↑

JNJ

190.85

-0.66%↓

ABT

126.63

+0.17%↑

MDT

93.85

-0.53%↓

VEEV

293.38

+0.69%↑

A

148.14

+0.67%↑

JNJ

190.85

-0.66%↓

ABT

126.63

+0.17%↑

MDT

93.85

-0.53%↓

VEEV

293.38

+0.69%↑

A

148.14

+0.67%↑

JNJ

190.85

-0.66%↓

ABT

126.63

+0.17%↑

MDT

93.85

-0.53%↓

VEEV

293.38

+0.69%↑

A

148.14

+0.67%↑

Search

Guardant Health Inc

Fechado

SetorSaúde

72.17 4.31

Visão Geral

Variação de preço das ações

24h

Atual

Mín

69.34

Máximo

72.53

Indicadores-chave

By Trading Economics

Rendimento

-4.7M

-100M

Vendas

29M

232M

Margem de lucro

-43.044

Funcionários

1,999

EBITDA

22M

-89M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+5.6% upside

Dividendos

By Dow Jones

Próximos Ganhos

29 de out. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

3.3B

8.8B

Abertura anterior

67.86

Fecho anterior

72.17

Sentimento de Notícias

By Acuity

21%

79%

45 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Guardant Health Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

23 de out. de 2025, 20:49 UTC

Ganhos

Correction to Thermo Fisher Article on Oct. 22

23 de out. de 2025, 23:51 UTC

Conversa de Mercado

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23 de out. de 2025, 23:49 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

23 de out. de 2025, 23:49 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23 de out. de 2025, 23:37 UTC

Conversa de Mercado

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23 de out. de 2025, 22:58 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

23 de out. de 2025, 22:57 UTC

Conversa de Mercado

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23 de out. de 2025, 22:49 UTC

Aquisições, Fusões, Aquisições de Empresas

How Trump Sparked a New Era of State Capitalism -2-

23 de out. de 2025, 22:49 UTC

Aquisições, Fusões, Aquisições de Empresas

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23 de out. de 2025, 22:17 UTC

Ganhos

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23 de out. de 2025, 21:41 UTC

Ganhos

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23 de out. de 2025, 21:05 UTC

Ganhos

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23 de out. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

23 de out. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Auto & Transport Roundup: Market Talk

23 de out. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

23 de out. de 2025, 20:35 UTC

Ganhos

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23 de out. de 2025, 20:28 UTC

Ganhos

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23 de out. de 2025, 20:15 UTC

Conversa de Mercado
Ganhos

Global Commodities Roundup: Market Talk

23 de out. de 2025, 20:10 UTC

Ganhos

Newmont Mining 3Q Adj EPS $1.71

23 de out. de 2025, 20:10 UTC

Ganhos

Newmont Mining 3Q Sales $5.52B

23 de out. de 2025, 20:10 UTC

Ganhos

Newmont Mining 3Q EPS $1.67

23 de out. de 2025, 20:09 UTC

Ganhos

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23 de out. de 2025, 20:07 UTC

Conversa de Mercado
Ganhos

Global Equities Roundup: Market Talk

23 de out. de 2025, 20:07 UTC

Conversa de Mercado
Ganhos

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23 de out. de 2025, 20:07 UTC

Ganhos

Blackstone Looks to IPOs for Investment Exits -- Update

23 de out. de 2025, 20:05 UTC

Ganhos

Intel 3Q Gross Margin 38.2% >INTC

23 de out. de 2025, 20:04 UTC

Ganhos

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23 de out. de 2025, 20:04 UTC

Ganhos

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23 de out. de 2025, 20:04 UTC

Ganhos

Intel: 4Q Guidance Excludes Altera >INTC

23 de out. de 2025, 20:04 UTC

Ganhos

Intel Sees 4Q Adj EPS 8c >INTC

Comparação entre Pares

Variação de preço

Guardant Health Inc Previsão

Preço-alvo

By TipRanks

5.6% parte superior

Previsão para 12 meses

Média 71.84 USD  5.6%

Máximo 90 USD

Mínimo 60 USD

Com base em 21 analistas de Wall Street que oferecem metas de preço de 12 meses para Guardant Health Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

21 ratings

21

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

38.86 / 47.41Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bullish Evidence

Sentimento

By Acuity

45 / 371 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat